Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo.

Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and failure-free survival. Equillium, Inc. seeks Breakthrough Therapy designation and Accelerated ...

While these positive results add to itolizumab’s critical mass of safety and efficacy data across different patient populations, we are particularly encouraged by this data in the context of our phase ...

Equillium (EQ) stock soared 26% on positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to severe ulcerative colitis. Read more here.

Itolizumab was generally well tolerated consistent with prior clinical experience. LA JOLLA, Calif., February 06, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology ...

Equillium (EQ) stock cratered 36% after the company said it was pausing certain programs due to Ono Pharmaceutical failing to exercise an option to acquire its drug itolizumab.

LA JOLLA, Calif. - Equillium Inc . (NASDAQ: NASDAQ:EQ), a biotechnology firm focused on developing treatments for autoimmune and inflammatory disorders, announced today that Ono Pharmaceutical Co., ...

Itolizumab is a monoclonal antibody targeting the CD6-ALCAM signaling pathway, which is implicated in several immuno-inflammatory diseases. The drug has orphan drug and fast track designations for ...

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire. Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025.

Equillium’s anti-CD6 monoclonal antibody itolizumab has shown promise in a late-stage study evaluating the drug as a treatment for graft versus host disease (GvHD). The biotech announced a positive ...